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Aim: To evaluate clinical significance and diagnostic utility of increase in serum PDGF-BB (sPDGF-BB) in esophageal cancer, which 
have not been addressed yet despite the relevance of PDGF axis in this cancer type. Methods: Immunoenzymatically assessed sPDGF-
BB was related to clinicopathological features, and inflammatory, angiogenic, and lymphangiogenic indices in 84 patients with esopha-
geal cancer and 47 controls. Its diagnostic utility was evaluated by receiver operating characteristics (ROC) curve analysis. Results: 
sPDGF-BB was significantly higher in esophageal cancer patients than controls (3.76 vs. 2.66 μg/l,  p = 0.0001) and corresponded with 
the disease advancement. Of evaluated clinicopathological features, lymph node metastases and distant metastases were independently 
associated with an increase in sPDGF-BB; however, only the association with lymph node metastases persist adjustment to platelets. 
In univariate analysis, sPDGF positively correlated with platelets (r=0.70, p < 0.0001), vascular endothelial growth factor (VEGF)-A 
(r=0.50, p < 0.0001), VEGF-C (r=0.57, p < 0.0001), white blood cells (r=0.32, p = 0.004), C-reactive protein (r=0.34, p = 0.004), 
IL-6 (r=0.35, p = 0.003), and IL-8 (r=0.45, p < 0.0001). In multivariate analysis, VEGF-C and platelets were independently associ-
ated with sPDGF-BB explaining 61% in its variability. With >2.845 μg/l cut-off, over 76% of patients had elevated sPDGF-BB. Its 
accuracy as lymph node metastases marker was 75%, sensitivity and specificity corresponding with >3.029 μg/l cut-off were 84 and 
61%, respectively. Conclusions: sPDGF-BB owns potential as a possible lymph node metastases marker and might be considered 
as a diagnostic tool in preliminary evaluation of esophageal cancer patients identifying those likely to be burdened with lymph node 
metastases, the disease recurrence monitoring, and/or preselecting patients for PDGF-directed cancer therapies.
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Esophageal cancer (EC) is the sixth most frequent 
malignancy worldwide and the fifth cause of cancer-
related deaths [1]. The disease is usually recognized 
late and by the time of its first clinical manifestations, 
the cancer has already metastasized, primarily to re-
gional then distant lymph nodes. The accurate staging 
in EC is of primary importance as the involvement of dis-
tant lymph nodes determines palliation. Moreover, sur-
vival rates following esophagectomy strongly depend 
on the number of metastatic lymph nodes as well as the 
number of lymph nodes resected whereas overlooked 
lymph nodes metastases remain the main culprit of dis-
ease recurrence [2, 3]. Currently applied diagnostic 
procedures either lack accuracy or, like an endoscopic 
ultrasound (EUS)-guided transesophageal biopsy 
of lymph nodes, are invasive and not universally avail-
able [4]. In this respect, the idea of biomarker evalua-
tion, relatively cheap, non-invasive, and easy to perform 
procedure, is appealing and lymphangiogenic factors 
seem to be the best candidates. Moreover, targeting 
angiogenesis and/or lymphangiogenesis is a promising 
anti-cancer treatment — relatively non-toxic in com-
parison with conventional radiochemotherapy and less 
prone to develop acquired drug resistance, and, yet, 
capable of inducing tumor shrinking, improving the con-
trol of metastasis and the delivery of chemotherapeutic 
agents into tumor cells [5, 6].
A family of platelet-derived growth factors (PDGFs) 
has recently emerged as a new potential source of bio-
markers and targets for anti-cancer treatment [7]. From 
among the family members, the isoform consisting 
of two B chains (PDGF-BB) has been recognized as the 
most potent lymphangiogenic factor. PDGF-BB is es-
sential for metastatic spread to lymph nodes and acts 
directly by inducing migration of lymphatic endothelial 
cells [8]. It also affects cancer-related angiogenesis 
by up-regulating vascular endothelial growth factor 
(VEGF)-A expression [9] and by controlling the process 
of pericyte recruitment during vessel maturation [10]. 
PDGF-BB is overexpressed by many cancer types 
of epithelial origin as well as by some host cells, that is, 
macrophages, fibroblasts and vascular smooth muscle 
and endothelial cells [11]. However, a-granules of plate-
lets remain the main storage site of this growth factor 
[11], which could be tumor-available following platelet 
activation and degranulation. Since both these process-
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es occur during clot formation, serum concentrations 
of PDGF-BB (sPDGF-BB) are believed to better reflect 
the platelet-stored PDGF-BB than its plasma levels [12].
Data on the possible association between PDGF-
BB and esophageal cancer are scanty, suggestive, 
however, of the relevance of PDGF axis in this cancer 
type [13, 14]. However, sPDGF-BB levels in EC have 
not been assessed before. Our objectives were 
to evaluate clinical significance of increase in sPDGF-
BB in EC as well as diagnostic potential of sPDGF-
BB as compared to VEGF-A and VEGF–C, the key 
angiogenic and lymphangiogenic factors.
MATERIALS AND METHODS
Study population. We enrolled 84 EC patients 
admitted to the Department of Gastrointestinal and 
General Surgery, Wroclaw Medical University, Wroclaw, 
Poland for conservative therapy, surgery, or pallia-
tive procedure, whose blood samples were collected 
on admission or soon afterwards, preceding any treat-
ment. Patients were staged clinically according to the 
guidelines of the UICC TNM [15] system on the basis 
of upper digestive tract endoscopy with biopsy and 
pathological examination, contrast radiographic stud-
ies with barium or gastrografin, posteroanterior and 
lateral chest radiography, ultrasound examination of the 
abdominal cavity and cervical nodes, thorax and ab-
dominal cavity computed tomography (CT), diagnostic 
laparotomy and thoracotomy, and bronchoscopy, where 
appropriate. There were 69 men and 15 women, median 
age 59 (range: 35–84). Number of patients by disease 
stage and histology is given in Table 1. 
Table 1. The association between serum PDGF-BB and clinicopathologi-
cal features of esophageal cancer
Feature sPDGF-BB [μg/l] p value PLT [·109/L] p value
Stage:
I/II (n=14)
III (n=23)
IV (n=47)
2.77 (1.8–4.25)
3.35 (2.62–4.28)
4.37 (3.77–5.06)*
0.018
244 (190–298)
264 (223–305)
310 (281–339)
0.041
Local advancement (T):
2 (n=11)
3 (n=28)
4 (n=45)
2.76 (1.64–4.63)
3.50 (2.92–4.20)*
4.25 (3.57–5.05)*
0.065
250 (183–317)
261 (236–286)
311 (278–345)
0.046
Regional metasta-
ses (N):
no (n=33)
yes (n=51)
2.99 (2.37–3.78)
4.36 (3.80–5.01)*
0.003
268 (233–302)
299 (271–327)
0.162
Distant metasta-
ses (M):
no (n=45)
yes (n=39)
3.22 (2.69–3.86)
4.50 (3.81–5.32)*
0.008
265 (236–295)
311 (280–343)
0.034
Histology:
scc (n=50)
adc (n=34)
3.75 (3.24–4.25)*
3.78 (2.98–4.79)*
0.958
283 (256–309)
293 (255–331)
0.649
Notes: scc — squamous cell carcinoma; adc — adenocarcinoma; *-signifi-
cantly different from healthy subjects.
The control group consisted of 47 blood donors, 
considered healthy on the basis of physical examina-
tion and routine blood tests, whose sera were kindly 
provided by Regional Center of Blood Donation and 
Therapeutics in Wroclaw, Poland. There were 41 men 
and 6 women, median age 50 (range: 42–59). There 
was no difference in gender distribution (p = 0.608) 
between study and control groups. Although both 
groups differed with respect to age, sPDGF-BB did 
not correspond with age in any group: r=0.08, p = 
0.363 in a whole cohort, r=-0.07, p = 0.514 in EC and 
r=-0.10, p = 0.510 in control group.
Ethical considerations. The study protocol was 
approved by the Medical Ethics Committee of Wroclaw 
Medical University, Wroclaw, Poland and the study was 
conducted in accordance with the Helsinki Declaration 
of 1975, as revised in 1983, and an informed consent 
has been obtained from all patients.
Analytical methods. sPDGF-BB was measured 
immunoenzymatically using Human PDGF-BB Strati-
kine ELISA kits provided by Strathmann Biotec GmbH 
(Hamburg, Germany) according to the manufactur-
er’s instructions. VEGF-A and -C were assayed using 
respective ELISA tests provided by IBL (Hamburg, Ger-
many). Serum high-sensitive C-reactive protein (CRP) 
was determined by immunoturbidimetric method 
with the Quantia-CRP UV from Tulip Diagnostics Ltd. 
(Goa, India), adjusted to the micro-manual procedure. 
Interleukin (IL)-1, 6 and 8, and tumor necrosis factor 
(TNF)-a were determined in sera by an enzyme double-
antibody indirect immunoassays with respective Peli-
Kine Compact human ELISA kits supplied by Sanquin 
(Amsterdam, the Netherlands). All other indices were 
measured by routine automatic procedures.
Statistical analysis. Data distribution was tested 
using the Kolmogorov-Smirnov normality test. If not 
otherwise stated, data are presented as means together 
with 95% CI and analyzed using the t-test for independent 
samples, Welch test or one way ANOVA, preceded by the 
comparison of variances (F-test or Levene’s test for 
equality of variances, respectively). Mann-Whitney U test 
was applied for age comparison. Correlation analysis 
was conducted with Pearson (r) or Spearman (ρ) cor-
relation tests. For interrelated variables, second-order 
coefficients of partial correlation (a “net” correlation be-
tween two variables of a larger group when the remaining 
variables are held constant) were calculated. Frequency 
analysis was carried out using χ2 test. Multiple regression 
analysis was conducted with a stepwise model (with 
p<0.05 as an entrance criterion and p>0.1 as a removal 
criterion). Missing data (CRP and interleukins) were 
handled by restricting the analyses involving CRP and 
IL to complete cases. Platelet count (PLT) was identified 
as a potential confounder and adjusted to by analysis 
of covariance (ANCOVA). All tests were two-sided and 
p values ≤0.05 were considered statistically significant.
sPDGF-BB diagnostic utility was evaluated with 
reference to VEGF-A and VEGF-C using Receiver 
Operating Characteristics (ROC) curve analysis. 
The overall performance was expressed as the area 
under the ROC curve (AUC) with 95% CI and p value 
for the difference between the calculated AUC and 
AUC=0.5 (index with no diagnostic power). Additional-
ly, a cut-off value corresponding with the highest accu-
racy (minimal false positives and false negatives) was 
determined. The related sensitivities and specificities 
were calculated and summarized in the Youden index 
(sensitivity+specificity-1) for comparative purposes. 
The likelihood ratios for positive (+LR) and negative 
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(-LR) results were calculated as well. Inter-rater agree-
ment was quantified using Κ-statistics. 
Entire statistical analysis was conducted using 
MedCalc® version 10.4.0.0 (Mariakerke, Belgium) 
with the exception of partial correlation coeffi-
cients calculated using VassarStats (available from 
http://faculty.vassar.edu/lowry/VassarStats.html).
RESULTS
sPDGF-BB in esophageal cancer — the as-
sociation with clinicopathological features. 
sPDGF-BB in EC patients were significantly higher 
than in healthy subjects (3.76 μg/l (95%CI: 3.31–4.27) 
vs. 2.66 μg/l (2.40–2.96), p = 0.0001). In EC patients, 
the increase in sPDGF-BB was associated with the 
disease advancement, particularly with the presence 
of regional and distant metastases, whereas sPDGF-
BB concentrations in less advanced cancers did not 
significantly differ from those observed in healthy sub-
jects. There were no differences in factor’s concentra-
tions between patients with squamous cell carcinomas 
and adenocarcinomas. Also PLT significantly differed 
with respect to the disease advancement (Table 1).
To identify factors independently associated with 
and increase in sPDGF-BB in a whole cohort, we per-
formed multiple regression analysis with sPDGF-
BB as response variable and cancer presence (0/1), 
disease stage, lymph node (0/1) and distant (0/1) 
metastases as explanatory variables. Of these, lymph 
node metastases (LNM) (p<0.001) and distant metas-
tases (p=0.002) were independently associated with 
the increase in sPDGF-BB. Also when the analysis was 
restricted to EC patients, LNM and distant metastases 
but not the disease stage were predictors of sPDGF-
BB. However, only the association with LNM was per-
tinent following PLT adjustment (p=0.033) by ANCOVA 
(sPDGF-BB as dependent variable, LNM and distant 
metastases as factors, and PLT as covariate).
Univariate and multivariate correlation analyses. 
sPDGF-BB in EC patients correlated positively with VEGF-
A (r=0.50, p < 0.0001), VEGF-C (r=0.57, p<0.0001), and 
platelets (r=0.70, p < 0.0001). Since all these variables 
were interrelated, we calculated second order partial 
correlation coefficients to evaluate the “net”correlations. 
sPDGF-BB remained correlated with VEGF-C and PLT 
(r=0.33, p=0.003 and r=0.48, p<0.0001, respectively) 
but not with VEGF-A (r=0.13, p=0.262).
sPDGF-BB correlated also with white blood cells 
(WBC) count (r=0.32, p=0.004) and other inflammatory 
indices, that is, CRP (r=0.34, p=0.004), IL-6 (r=0.35, 
p=0.003), and IL-8 (r=0.45, p<0.0001) but not with 
IL-1 (ρ=-0.05, p=0.711) or TNF-α (ρ=-0.04, p=0.768). 
Of the factors associated with sPDGF-BB in univariate 
analysis (PLT, WBC, CRP, IL-6, IL-8, VEGF-A, and VEGF-
C), PLT (b=0.016, p<0.0001) and VEGF-C (b=3.27, 
p=0.005) were independently associated with sPDGF-
BB in multiple regression analysis, explaining 61% in data 
variability (R2=0.61; const=-4.16; F=46.95, p<0.001). 
Diagnostic potential of sPDGF-BB. Using the 
cut-off values established in ROC analysis to opti-
mally differentiate diseased and healthy subjects 
(>2.845 μg/l for sPDGF-BB, >13.14 μg/l for VEGF-
C and >222 ng/l for VEGF-A), 76.2%, 72.7%, and 
63.4% of EC patients had elevated sPDGF-BB, VEGF-
C, and VEGF-A, respectively. 
The overall diagnostic accuracy of all growth factors 
was comparable. The sensitivity of sPDGF-BB using 
optimal cut-off values was higher than these of VEGF-
C and VEGF-A but the corresponding specificity was 
lower than calculated for VEGF-C (Table 2). The opti-
mal cut-off values are chosen assuming that sensitivity 
and specificity are equally important. However, in case 
of LNM detection, falsely negative predictions should 
be minimized thereby favoring high test sensitivity. Us-
ing optimal cut-offs, sPDGF-BB had the highest sen-
sitivity. For comparative purposes, we chose cut-off 
values for VEGF-A and VEGF-C to approach sensitivity 
calculated for sPDGF-BB. Using a new cut-offs with 
fixed high sensitivity, sPDGF-BB was the marker with 
the highest specificity and Youden index and favorable 
likelihood ratios (Table 2).
Table 2. Diagnostic potential of sPDGF-BB, VEGF-C and VEGF-A as indi-
cators of lymph node metastases
sPDGF-BB VEGF-C VEGF-A
AUC (95%CI), 
pAUC=0.5
0.75 (0.66–0.82), 
p<0.001
0.78 (0.70–0.85), 
p < 0.001
0.71 (0.63–0.79), 
p < 0.001
Optimal cut-off >3.029 μg/l >15.96 μg/l >173.8 ng/l
Sens. and Spec. 84.3 and 61.3% 69.6 and 80.8% 81.6 and 53.8%
Youden index 0.456 0.504 0.354
LR+ and LR- 2.18 and 0.26 3.62 and 0.48 1.77 and 0.34
Adjusted cut-off* >12.4 μg/l >142 ng/l
Sens. and Spec. 84.8 and 52.6% 83.7 and 50%
Youden index 0.374 0.337
LR+ and LR- 1.79 and 0.29 1.67 and 0.33
Notes: AUC — area under ROC curve; CI — confidence interval; Sens — sen-
sitivity; Spec — specificity; LR — likelihood ratios. *Cut-off values for VEGF-
C and VEGF–A have been changed to reach sensitivities comparable to that 
of sPDGF-BB.
Diagnostic potential of simultaneous evaluation 
of sPDGF-BB and VEGF-C. To evaluate the agreement 
between LNM predictions conducted on the basis of in-
crease in sPDGF-BB and VEGF-C concentrations (using 
optimal cut-offs), we applied Κ-statistics. Inter-rater 
agreement was fair with Κ=0.359. Therefore, we exam-
ined whether substantial improvement can be achieved 
with their simultaneous measurement. Optimal cut-off 
values determined previously in ROC analysis were 
used and a rule minimizing false negative results was 
applied: a test was considered positive when at least 
one marker was elevated above established cut-off 
values, whereas a test was considered negative only 
when both markers were below their thresholds. The 
diagnostic accuracy expressed in terms of AUC was 
0.730 (0.645–0.803), sensitivity and specificity were 
92.16 and 53.75%, Youden index was 0.459, LR+ and 
LR- were 1.99 and 0.15, respectively.
DISCUSSION
To the best of our knowledge, clinical and diagnos-
tic significance of the increase in sPDGF-BB in EC has 
not been addressed yet. Matsumoto et al. [14] showed 
up-regulated expression of PDGF-BB in EC tumors, 
which corresponded with the disease progression. 
Their results added to the in vitro findings on the fac-
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tor’s relevance for the growth promotion of EC. Liu 
et al. [13] demonstrated the presence of binding sites 
for PDGF-BB on tumor cells, which implies autocrine 
mode of action and provides the growth advantage 
and prevents apoptosis in esophageal carcinoma cell 
line. Correspondingly, we found increased sPDGF-
BB in EC patients as compared to healthy individuals. 
sPDGF-BB elevation was associated exclusively with 
advanced disease, particularly with the presence 
of regional and distant metastases. 
Advanced EC in our patients was also associated 
with increased platelet count, corroborating previous 
findings showing high PLT to correspond with EC pro-
gression and poor outcome [16]. Since platelets greatly 
contribute to serum PDGF-BB, reflected by high cor-
relation coefficient for sPDGF-BB and PLT in our pa-
tients, the associations we observed might be mediated 
by increase in platelets. Indeed, following adjustment 
to PLT, sPDGF-BB association with distant metastases 
lost its relevance. However, sPDGF-BB association with 
lymph node metastases remained significant and was 
further supported by a positive and independent from 
PLT correlation between sPDGF-BB and VEGF-C, a key 
lymphangiogenic factor [17]. Correspondingly, Onimaru 
et al. [18] demonstrated that both these growth factors 
are tightly associated, with VEGF-C regulating PDGF-
BB expression during capillary formation.
sPDGF-BB in our patients was also correlated with 
VEGF-A, IL-6, IL-8, CRP, and WBC, but, otherwise than 
in case of VEGF-C, all these correlations did not persist 
PLT adjustment. PDGF-BB has been shown to trigger 
VEGF-A expression in malignant and non-malignant 
settings [9, 19]. However, in our study the relationship 
reflected the close association of both growth factors 
with platelet count. Similarly to PDGF-BB, circulating 
VEGF-A is actively scavenged and stored in platelets, 
and released ex vivo during blood clotting [20, 21]. Also 
IL-8 is associated with angiogenic and lymphangiogenic 
potential of EC [22] and as such may be sequestered 
by platelets from circulation. Concerning IL-6, plate-
let mediation is consistent with the findings showing 
IL-6 to be a potent inductor of platelet production [23] 
and PDGF-BB to be preferably expressed isoform 
by megakaryocytes, platelets precursors [24]. IL-6 also 
induces CRP synthesis [25] and correlates with WBC 
and might mediate the association between sPDGF-
BB and these inflammatory indices. Accordingly, the 
correlation between IL-6 and CRP or WBC in our pa-
tients was stronger than found for sPDGF-BB, while cal-
culated partial correlations were significant for IL-6 and 
CRP or WBC but not for sPDGF-BB (data not shown).
Our finding on sPDGF-BB being associated with 
lymph node metastases is of clinical relevance. First, 
its assessment might be considered in preliminary 
evaluation of EC patients as an inexpensive, available, 
and non-invasive diagnostic tool for selecting those 
who are likely to be LNM positive. We found sPDGF-
BB specificity and sensitivity to be comparable to these 
reported for CT (sensitivity 84% and specificity 67% 
[4]) while its sensitivity was better than that reported for 
positron emission tomography with fluorine-18–2-flu-
oro-2-deoxy-D-glucose (FDG-PET; sensitivity 51% 
and specificity 84% [4]). Previously, Tamura et al. [26] 
demonstrated circulating lymphangiogenic growth fac-
tor, VEGF-C, to be a more accurate indicator of lymph 
node metastases in lung cancer than chest CT. Cor-
respondingly, we demonstrated VEGF-C to be equally 
accurate in LNM detection in esophageal squamous cell 
carcinoma [27]. In our present study, VEGF-C as LNM 
marker had the best Youden index and the overall ac-
curacy of all evaluated growth factors but, at its optimal 
cut-off, specificity was favored over sensitivity. Taking 
into account the results of clinical studies demon-
strating prolonged survival for patients with extended 
lymphadenectomy [3], from clinical point of view a false 
negative prediction is more critical for patient’s survival 
than a false positive one. Therefore, sensitivity is favored 
over specificity and LR- over LR+. sPDGF-BB had the 
highest sensitivity and, when cut-offs of other markers 
were adjusted to approach 85% sensitivity, it had also 
the highest specificity. Second, measuring sPDGF-
BB might be considered in monitoring of patients 
following esophagectomy as overlooked metastatic 
lymph nodes remain the main culprit of disease re-
currence [3]. Further studies are needed to evaluate 
sPDGF-BB as a possible indicator of micrometastases, 
which are easy to be missed during tissue sampling. 
The potential of lymphangiogenic factors in detect-
ing micrometastases is supported by the finding that 
the arrival of tumor cells into the nodes is preceded 
by lymph node lymphangiogenesis associated with 
overexpression of lymphangiogenic growth factors [17]. 
Fair inter-rater agreement between sPDGF-BB and 
VEGF-C as predictors of LNM inn our patients raised 
the possibility that their simultaneous evaluation may 
improve the diagnostic power of a single evaluation. 
Indeed, the sensitivity was slightly improved; however, 
specificity was reduced and the overall accuracy as well 
as Youden index for simultaneous evaluation of sPDGF-
BB and VEGF-C remained almost unaltered.
Another possible clinically relevant application 
of sPDGF-BB evaluation is identifying patients with 
high angiogenic/lymphangiogenic potential who are 
likely to benefit from angiogenesis and/or lymphan-
giogenesis directed therapies. It may also guide the 
selection of treatment that would suit the actual an-
giogenic/lymphangiogenic phenotype of a specific 
EC patient since pattern of growth factor expression 
varies by tumor type and changes during the disease 
progression. Moreover, there are inter-individual mo-
lecular differences that have to be taken into account 
while designing a treatment [5].
We evaluated PDGF-BB concentration in serum, 
although plasma is believed to better reflect circulating 
pool of this growth factor. However, serum concentra-
tions represent also PDGF-BB pool stored in platelets 
[12]. Taking into account that platelet-stored PDGF-
BB is easily available for the tumor and surrounding 
stroma due to complex action of thrombin [24, 28], 
sPDGF-BB better correspond with the true angio-
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genic/lymphangiogenic potential related to this growth 
factor. Moreover, Klement et al. [20] not only demon-
strated that platelets actively sequester angiogenic 
growth factors but, even more importantly, that dur-
ing cancer development the enlargement of platelet 
pool of angiogenic growth factors precedes their rise 
in plasma. Since sPDGF-BB is not an exact representa-
tion of PDGF-BB content in platelets as it might be se-
creted by several other cells [11], it would be of interest 
to evaluate in future studies whether EC is associated 
with increased load of PDGF-BB in individual platelets.
Summarizing, we demonstrated the increase 
in serum concentrations of PDGF-BB in esophageal 
cancer patients, exclusively associated with the pres-
ence of lymph node metastases. PDGF-BB association 
with lymphangiogenesis was supported by its cor-
relation with VEGF-C, independent from platelets, 
with the number of which sPDGF-BB was closely 
correlated. If confirmed in a larger study, sensitivity 
of sPDGF-BB as an indicator of lymph node metas-
tases, comparable to that of CT, suggest its clinical 
relevance as potential LNM biomarker in preliminary 
evaluation of EC patients, the disease recurrence 
monitoring, and/or preselecting patients for directed 
cancer therapies. 
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